HIV/AIDS Trials
Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.
Page 1 of 1 | Results 1 - 5 of 5
Daniel Skiest, MD
HIV,
Infection
Baystate Infectious Diseases Clinical Research
3300 Main Street
Springfield, MA 01199
The purpose of this study is to compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily to the DTG plus Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC] administered once daily in human immunodeficiency virus (HIV) 1 infected adult subjects that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC.
Dr. Daniel Skiest
Infection,
HIV
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
Peter D. Friedmann, MD
HIV
Baystate Medical Center, 759 Chestnut St, Springfield, MA
The purpose of this study is to test the efficacy of 4 mg Pitavastatin daily on cardiovascular-related events among HIV-1 infected adults.
Daniel J. Skiest, MD
HIV,
Heart
Baystate Infectious Diseases Clinical Research
3300 Main Street
Springfield, MA 01199
Durane Walker, MD
HIV,
Infection
Baystate Infectious Diseases Clinical Research,
3300 Main Street,
Springfield, MA
Page 1 of 1 | Results 1 - 5 of 5